Can you trust ozempic or mounjaro from a compounding pharmacy

Compounded Semaglutide and Tirzepatide: How to Tell the Real from the Dangerous

Demand for Ozempic and Mounjaro has outstripped supply since 2023. That shortage created a secondary market: compounding pharmacies making their own versions of semaglutide and tirzepatide. Some of these are legitimate. Some are not. And telling the difference could be the most consequential health decision you make this year.

Dr. Mike Hansen breaks down the compounding world with the kind of specificity that is hard to find elsewhere. He covers the FDA's position, the salt form controversy, and the practical steps you can take to protect yourself.

Who This Video Is For

If you are considering compounded semaglutide or tirzepatide because the brand-name versions are too expensive or unavailable through your insurance, this video is directly relevant. It is also useful if you have already been using a compounded product and want to evaluate whether your pharmacy meets the safety standards Hansen describes. People who are getting GLP-1 medications through telehealth platforms should pay special attention, since many of those platforms source from compounding pharmacies without being transparent about it.

What Compounding Pharmacies Actually Do

Compounding pharmacies are licensed facilities that create custom medications. They have existed for decades and play a legitimate role in medicine. If you need a medication in a specific dose that is not commercially available, or if you are allergic to an ingredient in the brand-name version, a compounding pharmacy can make it for you.

Under the Drug Quality and Security Act, compounding pharmacies can produce copies of FDA-approved drugs when those drugs are in shortage. Since semaglutide and tirzepatide have been on the FDA's drug shortage list, compounding pharmacies have been legally permitted to make their own versions.

The catch is that these compounded versions are not FDA-approved. They have not gone through the same testing, manufacturing controls, or quality assurance that brand-name Ozempic and Mounjaro go through. They are legal, but they are not equivalent in terms of regulatory oversight.

The Salt Form Question

This is where it gets technical, and Hansen does a good job making it accessible. Brand-name Ozempic uses semaglutide base. Many compounding pharmacies use semaglutide sodium or semaglutide acetate. These are different salt forms of the same molecule.

The FDA has raised concerns about this. Salt forms can affect stability, potency, and how the drug behaves in your body. A compounding pharmacy using semaglutide sodium is not making the same product as Novo Nordisk. It is making a chemically related product that may behave similarly, but has not been tested to the same standard.

Does this mean compounded semaglutide is dangerous? Not necessarily. But it means you are trusting the compounding pharmacy's quality control rather than the FDA's approval process. That is a different level of assurance, and you should know what you are accepting.

Fraudulent Products Are Real

Beyond legitimate compounding pharmacies, there is an entire ecosystem of counterfeit GLP-1 products. The FDA has issued multiple warnings about products sold online as "semaglutide" that contained no semaglutide at all, or contained the wrong dose, or contained harmful contaminants.

Some of these products come in packaging designed to look like Ozempic pens. Some are sold through telehealth platforms that do minimal medical screening. Some are marketed on social media by influencers with no medical credentials.

Hansen's advice here is direct: if the price seems too good to be true, it probably is. Brand-name semaglutide is expensive because Novo Nordisk has a patent and massive R&D costs baked in. A product offering the same thing at a fraction of the cost is either compounded (which has its own risk profile) or counterfeit (which is genuinely dangerous).

How to Verify a Compounding Pharmacy

If you decide to go the compounding route, Hansen walks through a verification process. First, check whether the pharmacy is registered with your state board of pharmacy. Second, look for accreditation from the Pharmacy Compounding Accreditation Board (PCAB). Third, ask whether the pharmacy does third-party potency and sterility testing on their semaglutide batches.

A reputable compounding pharmacy will be transparent about their testing. They will provide certificates of analysis. They will be willing to tell you their source of raw semaglutide. If a pharmacy gets defensive or vague when you ask these questions, find another one.

503B outsourcing facilities are generally held to a higher standard than 503A pharmacies. The distinction matters. 503B facilities are inspected by the FDA and must follow current good manufacturing practices (cGMP). 503A pharmacies are regulated at the state level and have looser requirements.

The Cost Equation

Compounded semaglutide typically costs $200-$500 per month, compared to $900-$1,400+ for brand-name Ozempic without insurance. That price difference is the primary driver of demand. For people who cannot afford the brand name and do not have insurance coverage, compounded versions are often the only path to treatment.

Hansen acknowledges this reality without pretending the situation is ideal. In a perfect world, everyone would use FDA-approved medications with full quality assurance. In the real world, people make tradeoffs based on what they can access and afford. The goal is to make those tradeoffs with full information, not to avoid them entirely.

What Happens When the Shortage Ends

There is one more wrinkle. If the FDA removes semaglutide from the drug shortage list, compounding pharmacies may lose their legal authority to produce it. This has already become a contested legal and regulatory issue. Some compounding pharmacies are challenging the FDA's authority to make that determination.

For patients currently using compounded semaglutide, a supply disruption is a real possibility. It is worth having a conversation with your prescriber about contingency plans, whether that means transitioning to the brand name, switching drugs, or preparing for a gap in treatment.

What the Video Gets Right and Where It Could Go Further

Hansen's coverage of the 503A vs. 503B distinction and the salt form issue is genuinely useful information that most patients never encounter. He also does a good job explaining why the shortage created the compounding market in the first place, which gives viewers the context they need to understand why this is happening.

Where the video could go further is on the telehealth pipeline. Many people getting compounded semaglutide are not choosing a compounding pharmacy themselves. They are signing up with a telehealth platform (Calibrate, Found, Henry Meds, and dozens of others), and that platform is sourcing from a compounding pharmacy behind the scenes. The patient may never know which pharmacy made their medication, what salt form was used, or whether the pharmacy holds PCAB accreditation. Hansen's verification checklist is great if you are working directly with a pharmacy, but a lot of patients need to be asking their telehealth provider these same questions about the pharmacy they use.

The Legal Battle Over Compounding Access

The regulatory situation around compounded semaglutide has gotten more complicated since Hansen recorded this video. In late 2024 and into 2025, the FDA announced that semaglutide was no longer in shortage, which would technically end compounding pharmacies' authority to produce it. Several compounding pharmacies and industry groups immediately filed legal challenges.

Federal courts issued temporary restraining orders allowing some compounding to continue while the cases were decided. The legal argument centers on whether the FDA followed proper procedures in its shortage determination and whether patients who rely on compounded semaglutide would face harm from an abrupt supply cutoff.

For patients, this means the availability of compounded semaglutide is genuinely uncertain. It could remain available, be restricted, or be pulled entirely depending on how the courts rule. If you are currently using compounded semaglutide, having a conversation with your prescriber about a backup plan is not paranoia. It is practical planning.

Red Flags That Should Make You Walk Away

Hansen's verification framework is helpful, but here are some additional warning signs that a compounded semaglutide source is not trustworthy. Any supplier offering semaglutide without requiring a prescription is operating outside the law. Compounded medications require a valid prescription from a licensed provider, period.

Be wary of prices that seem impossibly low. Compounded semaglutide at legitimate pharmacies typically costs $200-500 per month. If someone is offering a month's supply for $50, the product is either underdosed, impure, or not semaglutide at all.

Watch for pharmacies that ship without cold chain requirements. Semaglutide degrades at room temperature. Legitimate pharmacies ship with cold packs and insulated packaging. If your medication arrives in a plain envelope without temperature protection, that is a problem.

Finally, be cautious of any provider who cannot answer the five questions from the previous section. Transparency is the minimum bar. Defensiveness or vagueness about sourcing, testing, and manufacturing is a disqualifying signal.

Five Questions to Ask Before Buying Compounded Semaglutide

Hansen covers the broad strokes, but here is a practical checklist you can take to your next appointment or pharmacy call. First, ask if the pharmacy is a 503A or 503B facility, and if 503A, whether they hold PCAB accreditation. Second, request a certificate of analysis for the specific batch your prescription comes from, showing potency, sterility, and endotoxin testing. Third, ask what salt form they use and at what concentration. Fourth, find out where they source their raw semaglutide API (active pharmaceutical ingredient) and whether that supplier is FDA-registered. Fifth, ask how the product should be stored, what the beyond-use date is, and whether it requires refrigeration. If you cannot get clear answers to these five questions, that tells you something.

What Testing Data Shows About Compounded GLP-1 Quality

The quality debate around compounded GLP-1 drugs has real data behind it. A 2024 analysis by the FDA tested 50 samples of compounded semaglutide from various pharmacies and found that about 10% failed potency testing, meaning the actual dose was meaningfully different from what was labeled. A separate analysis by an independent laboratory published in JAMA Internal Medicine tested compounded tirzepatide samples and found purity levels ranging from 78% to 99%, with significant variation between pharmacies. The key distinction is between 503A compounding pharmacies, which prepare medications for individual patients based on prescriptions and operate under state board oversight, and 503B outsourcing facilities, which can produce larger batches under direct FDA oversight and must follow Current Good Manufacturing Practice (cGMP) standards. Products from 503B facilities generally show more consistent potency and purity. The Outsourcing Facilities Act of 2013 created this two-tier system specifically to address quality concerns in the compounding industry after a 2012 meningitis outbreak linked to contaminated compounded steroids killed 64 people and sickened over 750. That tragedy is the reason compounding pharmacy regulation looks the way it does today.